Clinical Trial Update: CATALINA-2: A Clinical Study of TORL-1-23 in Platinum-resistant Ovarian Cancer. [Phase 2]

View source ↗

Summary

A Phase 2 clinical study of TORL-1-23 is evaluating its activity in platinum-resistant ovarian cancer. The trial is currently recruiting across epithelial ovari…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Endometrioid Ovarian Cancer
• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Cancer

Drugs mentioned

• TORL-1-23

Snippet

Sponsor: TORL Biotherapeutics, LLC | Conditions: Epithelial Ovarian Cancer, Primary Peritoneal | Phase 2 | Status: RECRUITING